Filipe A. Moura, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myocardial Infarction | 8 | 2023 | 11727 | 0.600 |
Why?
|
Dyslipidemias | 3 | 2019 | 849 | 0.510 |
Why?
|
Diabetes Mellitus, Type 2 | 8 | 2024 | 11725 | 0.500 |
Why?
|
Insulin Resistance | 4 | 2019 | 3864 | 0.490 |
Why?
|
Insulin | 5 | 2019 | 6580 | 0.470 |
Why?
|
Endothelium, Vascular | 4 | 2021 | 4456 | 0.460 |
Why?
|
Periodicity | 1 | 2013 | 363 | 0.410 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2023 | 2208 | 0.340 |
Why?
|
Benzhydryl Compounds | 3 | 2023 | 845 | 0.310 |
Why?
|
Seasons | 1 | 2013 | 1493 | 0.300 |
Why?
|
Blood Glucose | 4 | 2021 | 6256 | 0.300 |
Why?
|
Cholesterol, HDL | 4 | 2019 | 1814 | 0.280 |
Why?
|
Cardiovascular Diseases | 5 | 2022 | 15165 | 0.280 |
Why?
|
Gastric Inhibitory Polypeptide | 2 | 2023 | 59 | 0.260 |
Why?
|
Diabetes Mellitus | 2 | 2022 | 5751 | 0.260 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2023 | 85 | 0.230 |
Why?
|
Niacin | 1 | 2014 | 116 | 0.230 |
Why?
|
Vasodilation | 3 | 2021 | 944 | 0.210 |
Why?
|
Lipoproteins, HDL | 2 | 2019 | 638 | 0.200 |
Why?
|
Brazil | 5 | 2021 | 1270 | 0.190 |
Why?
|
Plaque, Atherosclerotic | 1 | 2012 | 1519 | 0.190 |
Why?
|
Catheters | 1 | 2024 | 425 | 0.190 |
Why?
|
Glucosides | 2 | 2022 | 451 | 0.190 |
Why?
|
Glyburide | 1 | 2021 | 113 | 0.190 |
Why?
|
Hypoglycemic Agents | 3 | 2023 | 2872 | 0.180 |
Why?
|
Sarcopenia | 2 | 2017 | 368 | 0.180 |
Why?
|
Vasodilator Agents | 1 | 2014 | 977 | 0.170 |
Why?
|
Atherosclerosis | 2 | 2012 | 3445 | 0.170 |
Why?
|
Weight Gain | 2 | 2019 | 2292 | 0.160 |
Why?
|
Fatty Acids, Omega-3 | 2 | 2019 | 1344 | 0.150 |
Why?
|
Carotid Artery Diseases | 2 | 2021 | 882 | 0.150 |
Why?
|
Disease Progression | 2 | 2024 | 13284 | 0.150 |
Why?
|
Simvastatin | 1 | 2019 | 360 | 0.140 |
Why?
|
Overweight | 2 | 2019 | 2371 | 0.140 |
Why?
|
Coronary Artery Disease | 4 | 2024 | 6487 | 0.140 |
Why?
|
Glucose Clamp Technique | 2 | 2013 | 266 | 0.140 |
Why?
|
No-Reflow Phenomenon | 1 | 2015 | 14 | 0.140 |
Why?
|
Heart Valve Diseases | 1 | 2024 | 1073 | 0.140 |
Why?
|
Glomerular Filtration Rate | 1 | 2023 | 2170 | 0.130 |
Why?
|
Indoles | 1 | 2014 | 1839 | 0.130 |
Why?
|
Hydroxycholesterols | 1 | 2014 | 25 | 0.130 |
Why?
|
Brachial Artery | 1 | 2015 | 369 | 0.120 |
Why?
|
Environment Design | 1 | 2015 | 178 | 0.110 |
Why?
|
Inflammation | 3 | 2019 | 10638 | 0.110 |
Why?
|
Cooking | 1 | 2015 | 313 | 0.110 |
Why?
|
Frail Elderly | 2 | 2019 | 693 | 0.100 |
Why?
|
Risk Factors | 11 | 2023 | 72290 | 0.100 |
Why?
|
Aged | 14 | 2021 | 163280 | 0.100 |
Why?
|
Seafood | 1 | 2015 | 384 | 0.100 |
Why?
|
Ventricular Remodeling | 1 | 2019 | 1224 | 0.100 |
Why?
|
Middle Aged | 17 | 2023 | 213383 | 0.100 |
Why?
|
Age Factors | 5 | 2017 | 18370 | 0.090 |
Why?
|
Nonlinear Dynamics | 1 | 2013 | 502 | 0.090 |
Why?
|
Humans | 29 | 2024 | 744343 | 0.090 |
Why?
|
Arteries | 1 | 2014 | 1119 | 0.090 |
Why?
|
Sirtuins | 1 | 2012 | 323 | 0.090 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2020 | 2073 | 0.090 |
Why?
|
Coronary Angiography | 3 | 2017 | 4577 | 0.090 |
Why?
|
Prospective Studies | 7 | 2021 | 53288 | 0.090 |
Why?
|
Peripheral Arterial Disease | 2 | 2024 | 1188 | 0.090 |
Why?
|
Accidents, Traffic | 1 | 2015 | 819 | 0.090 |
Why?
|
Energy Intake | 1 | 2017 | 2148 | 0.080 |
Why?
|
Triglycerides | 2 | 2013 | 2454 | 0.080 |
Why?
|
Risk Assessment | 4 | 2023 | 23338 | 0.080 |
Why?
|
Sex Distribution | 1 | 2013 | 2297 | 0.080 |
Why?
|
Kidney | 1 | 2023 | 7186 | 0.080 |
Why?
|
Patient Admission | 1 | 2015 | 1380 | 0.080 |
Why?
|
ROC Curve | 1 | 2015 | 3527 | 0.080 |
Why?
|
Fasting | 1 | 2013 | 1593 | 0.080 |
Why?
|
Male | 17 | 2023 | 350118 | 0.080 |
Why?
|
Body Composition | 1 | 2017 | 2401 | 0.070 |
Why?
|
Age Distribution | 1 | 2013 | 2902 | 0.070 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39050 | 0.070 |
Why?
|
C-Reactive Protein | 2 | 2015 | 3778 | 0.070 |
Why?
|
Treatment Outcome | 6 | 2022 | 63114 | 0.070 |
Why?
|
Female | 17 | 2023 | 380194 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 3255 | 0.070 |
Why?
|
Nitric Oxide | 1 | 2015 | 2132 | 0.070 |
Why?
|
Aged, 80 and over | 6 | 2019 | 57776 | 0.060 |
Why?
|
Genome-Wide Association Study | 1 | 2024 | 12261 | 0.060 |
Why?
|
Stress, Physiological | 1 | 2011 | 1403 | 0.060 |
Why?
|
Cholesterol, LDL | 1 | 2013 | 2356 | 0.060 |
Why?
|
Enteroendocrine Cells | 1 | 2024 | 65 | 0.060 |
Why?
|
Lipids | 1 | 2015 | 3305 | 0.060 |
Why?
|
Aging | 2 | 2012 | 8664 | 0.060 |
Why?
|
Isoprostanes | 1 | 2022 | 21 | 0.060 |
Why?
|
Hyperglycemia | 1 | 2011 | 1373 | 0.050 |
Why?
|
Wounds and Injuries | 1 | 2015 | 2400 | 0.050 |
Why?
|
Sex Factors | 2 | 2013 | 10397 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 1 | 2024 | 17446 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
Muscle, Skeletal | 1 | 2017 | 4931 | 0.050 |
Why?
|
Delayed-Action Preparations | 1 | 2014 | 968 | 0.050 |
Why?
|
Receptor, Angiotensin, Type 2 | 1 | 2020 | 67 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 14722 | 0.050 |
Why?
|
Cross-Sectional Studies | 3 | 2019 | 25043 | 0.040 |
Why?
|
Logistic Models | 4 | 2017 | 13408 | 0.040 |
Why?
|
Echocardiography | 2 | 2024 | 5102 | 0.040 |
Why?
|
Heart Failure | 1 | 2023 | 10900 | 0.040 |
Why?
|
Ventricular Function, Left | 2 | 2023 | 3670 | 0.040 |
Why?
|
Hypolipidemic Agents | 1 | 2014 | 604 | 0.040 |
Why?
|
Stroke Volume | 2 | 2023 | 5007 | 0.040 |
Why?
|
Endothelial Cells | 2 | 2024 | 3479 | 0.040 |
Why?
|
Chloroquine | 1 | 2020 | 280 | 0.040 |
Why?
|
Time Factors | 3 | 2021 | 40075 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2014 | 2029 | 0.040 |
Why?
|
Cohort Studies | 2 | 2019 | 40561 | 0.040 |
Why?
|
Epigenomics | 1 | 2024 | 903 | 0.040 |
Why?
|
Takotsubo Cardiomyopathy | 1 | 2020 | 125 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 275 | 0.040 |
Why?
|
Cholesterol | 2 | 2019 | 2917 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 572 | 0.040 |
Why?
|
Islets of Langerhans | 1 | 2024 | 1352 | 0.040 |
Why?
|
Young Adult | 4 | 2019 | 56430 | 0.040 |
Why?
|
Diet | 1 | 2015 | 7939 | 0.040 |
Why?
|
Sphingosine | 1 | 2019 | 307 | 0.040 |
Why?
|
Adipocytes | 1 | 2024 | 1184 | 0.040 |
Why?
|
Lysophospholipids | 1 | 2019 | 331 | 0.040 |
Why?
|
Plasma | 1 | 2020 | 575 | 0.040 |
Why?
|
Diabetic Nephropathies | 1 | 2024 | 984 | 0.040 |
Why?
|
Multifactorial Inheritance | 1 | 2024 | 1194 | 0.040 |
Why?
|
Prevalence | 1 | 2013 | 15226 | 0.030 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 412 | 0.030 |
Why?
|
Platelet Aggregation | 1 | 2019 | 798 | 0.030 |
Why?
|
Virus Internalization | 1 | 2020 | 501 | 0.030 |
Why?
|
Portugal | 1 | 2015 | 87 | 0.030 |
Why?
|
Butter | 1 | 2015 | 22 | 0.030 |
Why?
|
Homeostasis | 2 | 2019 | 3340 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2019 | 35421 | 0.030 |
Why?
|
Soybean Oil | 1 | 2015 | 133 | 0.030 |
Why?
|
Metformin | 1 | 2021 | 835 | 0.030 |
Why?
|
Asymptomatic Diseases | 1 | 2017 | 551 | 0.030 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2019 | 591 | 0.030 |
Why?
|
Odds Ratio | 2 | 2017 | 9849 | 0.030 |
Why?
|
Nutrition Assessment | 1 | 2017 | 723 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2183 | 0.030 |
Why?
|
Fatty Acids, Omega-6 | 1 | 2015 | 227 | 0.030 |
Why?
|
Antimalarials | 1 | 2020 | 905 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2013 | 25625 | 0.030 |
Why?
|
Muscle Strength | 1 | 2017 | 592 | 0.030 |
Why?
|
Population Growth | 1 | 2012 | 52 | 0.030 |
Why?
|
Adult | 5 | 2021 | 214055 | 0.030 |
Why?
|
Chromatin | 1 | 2024 | 2934 | 0.030 |
Why?
|
Weight Loss | 1 | 2023 | 2622 | 0.030 |
Why?
|
Exercise Tolerance | 1 | 2017 | 770 | 0.030 |
Why?
|
Fishes | 1 | 2015 | 569 | 0.030 |
Why?
|
Neoplasms | 1 | 2020 | 21683 | 0.030 |
Why?
|
Antioxidants | 1 | 2019 | 1663 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4933 | 0.020 |
Why?
|
Infant | 1 | 2013 | 35136 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2017 | 1725 | 0.020 |
Why?
|
Blood Chemical Analysis | 1 | 2012 | 440 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6489 | 0.020 |
Why?
|
Child, Preschool | 1 | 2013 | 41006 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12245 | 0.020 |
Why?
|
Species Specificity | 1 | 2015 | 2478 | 0.020 |
Why?
|
Safety | 1 | 2015 | 1186 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2014 | 12026 | 0.020 |
Why?
|
C-Peptide | 1 | 2011 | 419 | 0.020 |
Why?
|
Exercise Test | 1 | 2017 | 2074 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2017 | 1372 | 0.020 |
Why?
|
Adolescent | 2 | 2015 | 85781 | 0.020 |
Why?
|
Nutritional Status | 1 | 2017 | 1609 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2019 | 3086 | 0.020 |
Why?
|
Animals | 3 | 2019 | 168757 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 2987 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2023 | 15076 | 0.020 |
Why?
|
Glucose | 1 | 2019 | 4397 | 0.020 |
Why?
|
Adiposity | 1 | 2017 | 1807 | 0.020 |
Why?
|
Hospitalization | 2 | 2019 | 10262 | 0.020 |
Why?
|
Fatty Acids | 1 | 2015 | 1809 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2019 | 3821 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2023 | 9959 | 0.020 |
Why?
|
Child | 1 | 2013 | 77709 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2012 | 15540 | 0.020 |
Why?
|
Insulin-Secreting Cells | 1 | 2011 | 891 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2011 | 6365 | 0.010 |
Why?
|
Up-Regulation | 1 | 2011 | 4217 | 0.010 |
Why?
|
Acute Disease | 1 | 2012 | 7149 | 0.010 |
Why?
|
Body Mass Index | 1 | 2019 | 12720 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 12745 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8388 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10388 | 0.010 |
Why?
|
Signal Transduction | 1 | 2019 | 23403 | 0.010 |
Why?
|
Incidence | 1 | 2012 | 20947 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20129 | 0.010 |
Why?
|
Prognosis | 1 | 2012 | 29063 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2015 | 77449 | 0.000 |
Why?
|